Complete response of advanced HER2-amplified lung adenocarcinoma to cadonilimab combined with disitamab vedotin: a case report
{{output}}
Background: Human epidermal growth factor receptor 2 (HER2) gene amplification in lung adenocarcinoma is associated with aggressive tumor behavior and poor prognosis. Currently, there is no standard targeted therapy for HER2-ampl... ...
